Nanhua Biotech announced that revenue for the first half of 2026 was 296 million yuan, up 473.56% year on year; net profit attributable to shareholders of listed companies was 5.9927 million yuan, a loss of 3.484,400 yuan in the same period last year, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4.317 million yuan, a loss of 6.6562 million yuan for the same period last year, turning a year-on-year loss into a profit.

Nanhua Biotech announced that revenue for the first half of 2026 was 296 million yuan, up 473.56% year on year; net profit attributable to shareholders of listed companies was 5.9927 million yuan, a loss of 3.484,400 yuan in the same period last year, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4.317 million yuan, a loss of 6.6562 million yuan for the same period last year, turning a year-on-year loss into a profit.